MedTech News
.................... by Andrew Celentano
Freenome’s lung cancer test receives FDA breakthrough status
The SimpleScreen test is designed to detect early lung cancer signals from a standard blood sample.
FastWave Medical earns FDA IDE approval for next-gen IVL system
FastWave Medical earned FDA investigational device exemption (IDE) approval for its next-generation intravascular lithotripsy (IVL) technology, the company announced today.
Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients
HENDERSON, Nev., Aug. 12, 2026 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, today announces that results utilizing its lateral flow prototype are highly correlated with results utilizing Volition’s established automated Nu.Q® NETs test in critically ill sepsis patients1 , thereby expanding beyond centralized laboratory testing.
For the tiniest patients, new tech brings clearer MRI images
Some of medicine’s smallest patients can present its biggest imaging challenges. An infant’s heart can be as small as a walnut, beating rapidly inside a body that will change dramatically as the child grows. Yet much of the equipment used in MRI comes in standard sizes better suited to adult bodies, and customized versions can cost thousands of dollars and take months or even years to manufacture.
Sweat sensor enables continuous noninvasive measurement of cholesterol
Now, a team led by Wei Gao, a professor in Caltech’s Cherng Department of Medical Engineering, has developed a stick-on patch capable of gathering lipid measurements by analyzing sweat. And it can do so not just once but continuously.
Bracco’s VueJect contrast system secures FDA and Health Canada approvals
The device will be sold initially in the US and Canada, with further submissions planned in additional markets.
Wandercraft wins FDA clearance for self-balancing exoskeleton
Wandercraft, a Paris-based robotics company, announced that the FDA has granted clearance for Eve, its personal self-balancing exoskeleton designed to support upright mobility.
BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial
FRANKLIN LAKES, N.J., Aug. 12, 2026 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with successful completion of enrollment in the PREVENT clinical trial evaluating Phasix™ Mesh for the prevention of incisional hernias.